Aytu BioPharmaAYTU +1.35%40 3-Year RORE % is 26.03 as of Mar. 2026. GuruFocus rates AYTU with a GF Score™ of 40/100 and a GF Value™ of $0.85 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 939 Drug Manufacturers companies, Aytu BioPharma ranks better than 72.63% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Aytu BioPharma's 3-Year RORE % for the quarter that ended in Mar. 2026 was 26.03%.
The industry rank for Aytu BioPharma's 3-Year RORE % or its related term are showing as below:
AYTU's 3-Year RORE % is ranked better than 72.63% of 939
companies
in the Drug Manufacturers industry
Industry Median: 3.06
vs AYTU: 26.03
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Aytu BioPharma 3-Year RORE % Related Terms
Aytu BioPharma 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Aytu BioPharma's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AYTU vs TXMD, CPHI, RMTI: 3-Year RORE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aytu BioPharma 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Aytu BioPharma's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Aytu BioPharma (AYTU) has a 3-Year RORE % of 26.03 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aytu BioPharma and its competitors. According to the industry distribution chart, Aytu BioPharma ranks #257 out of 939 companies in the Drug Manufacturers industry, placing it in the top 27.4%.
Is Aytu BioPharma's 3-Year RORE % too high?
Aytu BioPharma's current 3-Year RORE % is 26.03. The Drug Manufacturers industry median 3-Year RORE % is 3.06. Aytu BioPharma's value of 26.03 is 750.7% above this industry median. Based on the distribution chart, Aytu BioPharma ranks #257 out of 939 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aytu BioPharma has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aytu BioPharma's 3-Year RORE % compare to TXMD and CPHI?
According to the Drug Manufacturers industry distribution chart, Aytu BioPharma ranks #257 out of 939 companies for 3-Year RORE %. This puts Aytu BioPharma in the upper half of its industry. The industry median 3-Year RORE % is 3.06. Aytu BioPharma's value of 26.03 is 750.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.06, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aytu BioPharma's current 3-Year RORE % of 26.03 is 750.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aytu BioPharma and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aytu BioPharma's current 3-Year RORE % is 26.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aytu BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Aytu BioPharma (AYTU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.85, compared to a current price of $2.25 — trading 164.7% above its estimated fair value. The current 3-Year RORE % is 26.03 and 750.7% above the Drug Manufacturers industry median of 3.06. Aytu BioPharma's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Aytu BioPharma (AYTU), the current 3-Year RORE % is 26.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aytu BioPharma (AYTU) Overvalued in 2026?
Based on GuruFocus' analysis, Aytu BioPharma stock appears to be overvalued.
The current stock price of $2.25 is trading 164.7% above its estimated GF Value™ of $0.85.
GuruFocus considers Aytu BioPharma to be Significantly Overvalued.
Key valuation signals for AYTU:
3-Year RORE %: 26.03
GF Value™: $0.85 vs. price of $2.25 (164.7% above fair value)
Industry Position: 750.7% above the Drug Manufacturers median (#257 of 939)
No single metric tells the full story. See the AYTU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
40GF Score
Get the complete analysis for AYTU
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AYTU has been successfully added to your 
